Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity
Cumberland Pharmaceuticals Inc. has transformed from a commercial-stage pharma to a pre-revenue, Phase 2-stage biotech focused on rare diseases. Recent $100M asset sale to Apotex funds operations and pipeline, with a special dividend paid to shareholders and four late-stage clinical programs retained. All pipeline assets are based on ifetroban, targeting high-value indications like DMD cardiomyopathy, cancer metastasis, systemic sclerosis, and IPF.
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
Cumberland Pharmaceuticals NASDAQ: CPIX reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health.
Possible Generic Drug Tariffs and 2 Microcaps
Generic drug tariffs could impact ELTP and CPIX.
Cumberland's Ifetroban Shows Potential to Limit Metastasis
CPIX reports positive Phase 2a results for Ifetroban, showing a favorable safety profile and promising early signs of reducing cancer metastasis in high-risk patients.
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan
CPIX posts a wider y//y loss in Q1, as it unveils a $100-million Apotex deal and sharpens focus on orphan drug development.
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2026 Earnings Call Transcript
Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales
CPIX's Q4 revenues jump 31%, while loss narrows year over year as sales of Vibativ, Sancuso and new product Talicia boosted its performance.
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2025 Earnings Call Prepared Remarks Transcript
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2025 Earnings Call Prepared Remarks Transcript
Niche Focus & Regulation Shape the Future of Healthcare Firms
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.
Zacks Initiates Coverage of CPIX With Outperform Recommendation
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates Cumberland as "Outperform." Explore how CPIX's scalable commercial model, long-duration Talicia revenues and pipeline upside create an attractive risk-reward setup for investors.
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants A. J. Kazimi - Founder, Chairman, President & CEO John Michael Hamm - VP & CFO Todd M.
